Document is current
Any future updates will be listed below
-
Authors
Kuwana, Masataka https://orcid.org/0000-0001-8352-6136
Tomiyama, Yoshiaki https://orcid.org/0000-0001-7645-0989
-
Funding
Funding for this research was provided by:
Kissei
- License Information
-
More Information
Article History
Received: 30 October 2024
Revised: 14 January 2025
Accepted: 15 January 2025
First Online: 28 January 2025
Declarations
:
: Masataka Kuwana has received grants or contracts from Boehringer Ingelheim International GmbH and Ono Pharmaceutical Co., Ltd.; royalties or licenses from Medical & Biological Laboratories Co., Ltd.; consulting fees from Kissei Pharmaceutical Co., Ltd., Boehringer Ingelheim International GmbH, and Mochida Pharmaceutical Co., Ltd., Glaxo Smith Kline K.K., Astra Zeneca K.K., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., Biogen Japan Ltd., and Novartis Pharma K.K.; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Boehringer Ingelheim International GmbH, Astellas Pharma Inc., and Asahi Kasei Pharma Corporation; and participated on a Data Safety Monitoring Board or Advisory Board at Argenx. Yoshiaki Tomiyama has received support for the present manuscript (e.g., funding, provision of study materials, medical writing, and article processing charges) from Kissei Pharmaceutical Co., Ltd.; consulting fees from Kissei Pharmaceutical Co., Ltd., Novartis Pharma K.K., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical, Argenx and Megakaryon Corporation; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Kissei Pharmaceutical Co., Ltd., Novartis Pharma K.K., Kyowa Kirin Co., Ltd., and UCB Japan Co. Ltd.; payment for expert testimony from Swedish Orphan Biovitrum AB and Sanofi; and participation on a Data Safety Monitoring Board or Advisory Board at Novartis Pharma K.K..
: This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. This study was approved by the institutional review board of each participating institution. All patients gave written informed consent before any study procedures were undertaken and again before participating in the washout period and period III.
